Uniklar Iv Injection Liyofilize Powder Iceren Vial

Uniklar IV Injection is a parenteral antibiotic medication containing clarithromycin 500 mg as its active ingredient. This medication is available in the form of a lyophilized powder that requires reconstitution before intravenous administration. As a macrolide antibiotic, Uniklar IV plays a crucial role in treating various bacterial infections, particularly when oral administration is not feasible or when a more rapid therapeutic effect is desired. This comprehensive guide provides detailed information about Uniklar IV, including its composition, mechanism of action, therapeutic applications, and proper administration guidelines.

What is Uniklar IV?

Uniklar IV Injection (Uniklar Iv Injection Liyofilize Powder Iceren Vial) is a sterile, lyophilized formulation of clarithromycin, a semi-synthetic macrolide antibiotic. The term “liyofilize powder iceren vial” indicates that the medication is supplied as a freeze-dried powder in a vial, which is a common pharmaceutical preparation method to ensure stability. Manufactured by Mustafa Nevzat, a Turkish pharmaceutical company, this medication is primarily marketed in Turkey and neighboring regions. The lyophilized formulation ensures stability and potency of the active ingredient until it is reconstituted for administration.

Composition

Each vial of Uniklar IV contains 500 mg of clarithromycin as the active pharmaceutical ingredient. The lyophilized powder form allows for extended shelf life and stability prior to reconstitution. This formulation represents an important alternative delivery method for patients who cannot take oral medications or require more rapid therapeutic intervention for serious infections.

Mechanism of Action

Clarithromycin, the active ingredient in Uniklar IV, belongs to the macrolide class of antibiotics. Its antimicrobial action stems from its ability to bind to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. By disrupting this essential cellular function, clarithromycin effectively stops the growth and multiplication of bacteria. It works by preventing certain types of bacteria from making the proteins they need to grow and multiply, which ultimately leads to the death of the bacterial cells or prevents their proliferation.

The medication exhibits a broad spectrum of activity against many gram-positive and gram-negative bacteria, making it versatile for treating various types of infections. It is bacteriostatic against many organisms but may be bactericidal at higher concentrations or against particularly susceptible bacteria.

Therapeutic Uses

Upper Respiratory Tract Infections

Uniklar IV is effective in treating infections of the upper respiratory tract, including pharyngitis (throat inflammation), tonsillitis (inflammation of the tonsils), and acute maxillary sinusitis (sinus inflammation). These infections, when caused by susceptible microorganisms such as Streptococcus pyogenes, respond well to clarithromycin therapy. The medication’s ability to achieve adequate tissue concentrations makes it particularly useful for these types of infections.

Lower Respiratory Tract Infections

For infections affecting the lower respiratory system, such as acute bacterial exacerbation of chronic bronchitis and pneumonia, Uniklar IV provides effective antimicrobial coverage. It targets pathogens commonly implicated in these conditions, including Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. The intravenous formulation ensures rapid and effective delivery of the antibiotic to the infection site.

Skin and Soft Tissue Infections

Uncomplicated skin and soft tissue infections caused by susceptible bacteria can be effectively treated with Uniklar IV. The medication demonstrates activity against common skin pathogens such as Staphylococcus aureus and Streptococcus pyogenes. For patients with severe infections or those unable to tolerate oral medications, the intravenous formulation provides an important treatment option.

Mycobacterial Infections

Uniklar IV has shown significant efficacy in the treatment of infections caused by various mycobacterial species, including Mycobacterium avium complex (MAC). For individuals with advanced HIV infection, this medication can help prevent disseminated MAC infections, which are a significant cause of morbidity and mortality in this population.

H. pylori Eradication

Clarithromycin plays a crucial role in combination therapy regimens aimed at eradicating Helicobacter pylori, a bacterium associated with peptic ulcer disease. By eliminating this pathogen, Uniklar IV contributes to the healing of peptic ulcers and reduces the risk of recurrence. The intravenous formulation may be used in patients who cannot tolerate oral medications or have severe disease requiring hospitalization.

Additional Therapeutic Applications

Beyond its primary indications, Uniklar IV may also be employed in the treatment of dental infections and other localized or systemic bacterial infections caused by susceptible organisms. Its broad spectrum of activity makes it a versatile choice for empiric therapy when the causative organism is not yet identified but is likely to be susceptible to clarithromycin.

Preparation and Administration

Reconstitution Process

As a lyophilized product, Uniklar IV requires proper reconstitution before administration. The process involves adding an appropriate diluent to the vial containing the powder. Typically, bacteriostatic water for injection is used for this purpose. The reconstitution process must be performed using aseptic technique to maintain sterility:

1. First, wash hands thoroughly and assemble necessary supplies on a clean surface.

2. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol pad.

3. Using a mixing syringe, withdraw the appropriate amount of bacteriostatic water.

4. Insert the needle into the vial containing the lyophilized medication and slowly transfer the bacteriostatic water.

5. Gently rotate the vial to ensure complete dissolution of the powder, resulting in a clear solution ready for administration.

Administration Guidelines

Uniklar IV should be administered as an intravenous infusion over a period of 60 minutes. It is recommended to infuse the medication into one of the larger proximal veins to minimize the risk of phlebitis or vascular irritation. Direct intravenous push or bolus administration should be avoided to prevent adverse reactions and ensure proper distribution of the medication throughout the bloodstream.

Dosage and Administration

Recommended Dosage for Adults

For adult patients, the standard recommended dosage of Uniklar IV is 1 gram daily, divided into two equal doses of 500 mg each. Each dose should be infused over 60 minutes, with a 12-hour interval between doses. The duration of therapy typically ranges from 7 to 14 days, depending on the nature and severity of the infection being treated.

Special Populations

For elderly patients or those with renal impairment, dosage adjustment may be necessary. In patients with severe renal dysfunction (creatinine clearance less than 30 mL/min), the dose should generally be reduced by 50%. Hepatic impairment may also necessitate dose adjustments, as clarithromycin is metabolized primarily in the liver.

Duration of Treatment

The duration of Uniklar IV therapy varies according to the type and severity of infection. For most respiratory tract infections, a 7 to 14-day course is typical. For mycobacterial infections, longer treatment periods may be required. It is essential to complete the full course of treatment as prescribed, even if symptoms improve before completion, to ensure eradication of the infecting organisms and prevent the development of resistance.

Side Effects and Adverse Reactions

Common Side Effects

Like all medications, Uniklar IV may cause certain side effects. Common adverse reactions include gastrointestinal disturbances such as nausea, diarrhea, vomiting, and abdominal discomfort. Some patients may experience headaches, altered taste sensation (dysgeusia), and mild skin reactions. These side effects are generally transient and resolve with continued therapy or upon discontinuation of the medication.

Serious Side Effects

Though less frequent, serious side effects may occur with Uniklar IV. These include severe diarrhea (potentially indicating pseudomembranous colitis), significant allergic reactions, and severe skin reactions. Hepatic dysfunction, characterized by elevated liver enzymes or clinical signs of liver damage, has been reported. Prolongation of the QT interval, which may lead to cardiac arrhythmias, is another potential concern, particularly in susceptible individuals.

When to Seek Medical Attention

Patients should seek immediate medical attention if they experience severe diarrhea, signs of allergic reaction (such as rash, itching, swelling, or difficulty breathing), unusual heart rhythms, or signs of liver problems (including yellowing of the skin or eyes, dark urine, or persistent nausea). Any persistent or worsening side effects should also prompt medical consultation.

Precautions and Contraindications

Uniklar IV is contraindicated in patients with known hypersensitivity to clarithromycin, erythromycin, or any other macrolide antibiotic. It should also be avoided in patients with a history of allergic reactions to any component of the formulation.

Drug Interactions

Clarithromycin interacts with numerous medications, primarily due to its inhibition of the cytochrome P450 enzyme system. Concurrent administration with medications such as astemizole, cisapride, pimozide, terfenadine, ergotamine, dihydroergotamine, lovastatin, or simvastatin is contraindicated due to the risk of serious adverse effects. Caution is advised when using Uniklar IV with other medications metabolized by the CYP3A4 enzyme system.

Use in Pregnancy and Lactation

The safety of clarithromycin during pregnancy has not been conclusively established. It should be used during pregnancy only when the potential benefits outweigh the risks. Clarithromycin is excreted in breast milk, and nursing mothers should either discontinue breastfeeding or discontinue the medication, taking into account the importance of the therapy to the mother.

Storage and Handling

Uniklar IV vials should be stored at controlled room temperature (15-30°C or 59-86°F) and protected from light. The reconstituted solution should be used promptly, as per the manufacturer’s guidelines regarding stability after reconstitution.

Shelf Life and Disposal

The lyophilized powder has a shelf life specified by the manufacturer, typically 2-3 years when stored under proper conditions. It is essential to check the expiration date before use and discard if expired. Used vials and administration equipment should be disposed of properly in accordance with local regulations for the disposal of pharmaceutical products and sharp objects.

Information Table